76 years old | 0
woman | 0
subjective fevers | 0
nonproductive cough | 0
dyspnea | 0
admitted to the intensive care unit | 0
acute hypoxic respiratory failure | 0
COVID-19 infection | 0
blood pressure 110/53 mm Hg | 0
pulse rate 124 beats/min | 0
respiratory rate 31 breaths/min | 0
oxygen saturation 79% | 0
temperature 102.3Â°F | 0
severe respiratory distress | 0
tachycardia | 0
diffusely decreased breath sounds | 0
crackles | 0
hypertension | 0
hyperlipidemia | 0
hypothyroidism | 0
acute dyspnea | 0
hypoxia | 0
COVID-19-induced acute respiratory distress syndrome | 0
acute pulmonary embolism | 0
acute heart failure | 0
septic shock | 0
cardiac tamponade | 0
acute coronary syndrome | 0
viral pneumonia | 0
bacterial pneumonia | 0
viral cardiomyopathy | 0
potassium 2.2 mEQ/L | 0
creatinine 1.79 mg/dL | 0
C-reactive protein 23.10 mg/L | 0
interleukin-6 781.46 mg/L | 0
lactate dehydrogenase 334 U/L | 0
ferritin 457 ng/mL | 0
procalcitonin 15.20 ng/mL | 0
prothrombin time 18.9 seconds | 0
fibrinogen >600 mg/dL | 0
white blood cell count 16.1 cells/L | 0
92.7% neutrophils | 0
IgG 1622 mg/dL | 0
SARS-CoV-2 positive | 0
troponin 0.03 ng/dL | 0
high-sensitivity troponin peaked at 503 ng/L | 0
proBNP 35,000 pg/mL | 0
diffuse bilateral pulmonary edema vs infiltrates | 0
worsening diffuse bilateral pulmonary opacities/infiltrates vs edema | 0
electrocardiogram no signs of ischemia | 0
normal sinus rhythm | 0
short PR interval 72 ms | 0
left ventricular hypertrophy | 0
QTc interval 680 ms | 0
previous echocardiograms normal LV ejection fraction | 0
no wall motion abnormalities | 0
transthoracic echocardiogram severely decreased LV systolic function | 0
segmental wall motion abnormalities | 0
akinesis of the distal segments of the left ventricle | 0
preserved function at the base | 0
akinesis of the mid and distal portions of the right ventricle | 0
preserved function at the base of the free wall | 0
ejection fraction 25%-30% | 0
intubated | 0
limited bedside TTE normal cardiac EF 55% | 0
shock state | 0
vasopressor support with norepinephrine | 0
ARDSnet protocol | 0
treated with tocilizumab 480 mg | 0
treated with tocilizumab 240 mg | 0
intravenous immunoglobulin 25 g for 5 days | 0
ceftriaxone | 0
cefdinir | 0
cefepime | 0
cytokine storm | 0
leukocytosis | 0
not treated with hydroxychloroquine | 0
not treated with azithromycin | 0
prolonged QTc interval | 0
worsening bilateral airspace opacities vs vascular congestion | 0
treated with intravenous furosemide 40 mg | 0
cardiac enzymes elevated | 0
repeat bedside TTE LVEF 20%-25% | 0
severe viral myocarditis | 0
transferred to a tertiary center | 0
LVEF 25%-30% | 0
wall motion abnormalities | 0
non-ST-elevation myocardial infarction | 0
treated with therapeutic enoxaparin | 0
LVEF recovered to 50% | 48
mildly reduced LV systolic function | 48
mid-septal and apical hypokinesis | 48
mildly reduced right ventricular function | 48
blood cultures negative | 48
respiratory cultures negative | 48
inflammatory markers improved | 48
inflammatory markers worsened again | 48
IL-6 downtrend from 781.46 mg/L to 171.82 mg/L | 48
high-sensitivity troponin decreased from 503 ng/L to 418 ng/L | 48
not candidate for extracorporeal membrane oxygenation | 48
transferred back to intensive care unit | 48
SARS-CoV-2-induced myocardial injury | 0
acute myocardial injury | 0
hemodynamic instability | 0
viral myocarditis | 0
Takotsubo cardiomyopathy | 0
therapeutic enoxaparin | 0
early cardiac biomarkers | 0
noninvasive imaging | 0
cardiology involvement | 0
cardiac complications | 0
dyspnea |$|$0
